As I'm reading the book, I'm starting to think we're already in the process of doing some backasswards special purpose aquisition company (SPAC) hybrid where the toxics are the SPAC, we commons are the cornerstone investors, and the subs function as the shells except because they're not actually shells, they can still raise money via reg A+ or something else and IPO.
(1)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links